Myriad Genetics (MYGN) Payables (2010 - 2026)

Myriad Genetics has disclosed Payables across 17 years of filings, most recently posting $32.6 million for Q1 2026.

• In Q1 2026, Payables rose 16.01% year-over-year to $32.6 million; the TTM figure through Mar 2026 stood at $32.6 million (up 16.01% YoY), while the FY2025 annual figure was $30.0 million, down 7.12% from the prior year.
• Payables grew to $32.6 million in Q1 2026, from $30.0 million in the prior quarter.
• Over the last five years, Payables for MYGN reached as high as $39.8 million in Q2 2023 and fell as low as $21.7 million in Q2 2022.
• The 5-year median for Payables is $30.9 million (2025), against an average of $30.9 million.
• The widest YoY moves for Payables: up 88.54% in 2022, down 23.86% in 2022.
• A 5-year view of Payables shows it stood at $28.8 million in 2022, then retreated by 10.42% to $25.8 million in 2023, then grew by 25.19% to $32.3 million in 2024, then dropped by 7.12% to $30.0 million in 2025, then rose by 8.67% to $32.6 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $32.6 million, $30.0 million, and $31.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.